key: cord-0926038-4rybl3rt
authors: Allen, Niamh; Brady, Melissa; Carrion Martin, Antonio Isidro; Domegan, Lisa; Walsh, Cathal; Doherty, Lorraine; Riain, Una Ni; Bergin, Colm; Fleming, Catherine; Conlon, Niall
title: Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals
date: 2021-08-09
journal: J Infect
DOI: 10.1016/j.jinf.2021.08.012
sha: ddd86e02750766b2f4c3d4adfcd1da826bd0eded
doc_id: 926038
cord_uid: 4rybl3rt

nan

As part of a large seroprevalence study in hospital healthcare workers (PRECISE 2 (4)), we measured antibody response following vaccination in over 4000 hospital healthcare workers (HCW), coupled with a questionnaire about previous symptoms and confirmed infection. We (1) . Vaccine effectiveness studies will also incorporate periodic serological testing for SARS-CoV-2 antibodies as a marker of breakthrough infection (9) . To the best of our knowledge there are no published data to date that have identified a comparative reduction in anti-N seroconversion following natural infection in vaccinated individuals. Whilst our numbers are small, even in large seroprevalence studies numbers of breakthrough infections will be small (5) , and further research of individuals with well-defined vaccine breakthrough infections are required. This information will be critical in informing optimal assessment of seroprevalence in vaccinated cohorts.

Impact of COVID-19 vaccination program on seroprevalence in blood donors in England

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis

Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid

Prevalence of Antibodies to SARS-CoV-2 natural infection and post-vaccination in Irish Hospital Healthcare Workers

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients

Identification of natural SARS-CoV-2 infection in seroprevalence studies among vaccinated populations

World Health Organisation; evaluation of COVID-19 vaccine effectiveness